News & Updates
Showing Oncology articles
Showing
Age, motion sickness tied to chemo-induced nausea, vomiting in children with cancer
In children with cancer receiving chemotherapy, factors such as age and susceptibility to motion sickness are associated with the risk of acute chemotherapy-induced nausea (CIN), reports a study.
Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?
Cancer patients who are being treated with chemotherapy are susceptible to chemotherapy-induced nausea and vomiting (CINV), and they continue to experience these side effects despite being administered with antiemetics, a study has shown.
Ginseng may protect breast cancer patients against doxorubicin-induced cardiac toxicity
Supplementation with ginseng appears to provide protective benefits against early cancer therapeutics-related cardiac dysfunction caused by doxorubicin and may help prevent early decline in left ventricular ejection fraction in patients with breast cancer, suggests a study.
Resistance exercise prevents ADT-induced muscle loss in patients with prostate cancer
Resistance exercise training counters the negative effects of androgen deprivation therapy (ADT) and improves muscle fibre size, as well as capillarization, in patients with prostate cancer, reports a study.
ICI-related adverse events tied to longer survival in metastatic NSCLC
Immune-related adverse events (irAEs) are more likely to develop in metastatic nonsmall cell lung cancer (NSCLC) patients with certain prognostic characteristics, suggests a study. Interestingly, those who develop irAEs benefit from a much longer overall survival (OS) and time to next treatment when mitigating immortal time bias.
Canakinumab improves survival in advanced NSCLC
Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.
Adjuvant trastuzumab for HER2-positive early BC: 9 weeks or 1 year?
For patients with HER2-positive early breast cancer (BC), 1 year of adjuvant trastuzumab remains standard of care (SoC) as noninferiority is not demonstrated for a shortened 9-week course of treatment in the final analysis of the phase III ShortHER trial. However, long-term data from the trial provide reassurance in case early discontinuation is needed in low-risk patients.